SEC Comment Letter 0000000000-23-008962 to Petros Pharmaceuticals, Inc. (PTPI)
Petros Pharmaceuticals, Inc.
Date: Aug. 16, 2023 · CIK: 0001815903 · Accession: 0000000000-23-008962
AI Filing Summary & Sentiment
File numbers found in text: 333-273935
Letter
United States securities and exchange commission logo August 16, 2023 Fady Boctor President and Chief Commercial Officer Petros Pharmaceuticals, Inc. 1185 Avenue of the Americas, 3rd Floor New York, NY 10036 Re:Petros Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed August 11, 2023 File No. 333-273935 Dear Fady Boctor: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jayun Koo, Esq.
Show Raw Text
United States securities and exchange commission logo
August 16, 2023
Fady Boctor
President and Chief Commercial Officer
Petros Pharmaceuticals, Inc.
1185 Avenue of the Americas, 3rd Floor
New York, NY 10036
Re:Petros Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed August 11, 2023
File No. 333-273935
Dear Fady Boctor:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jayun Koo, Esq.